Slingshot Insights | Statins Overview

STATINS Overview

Upcoming Projects (STATINS)

Don’t see a project related to the keyword you care about? Create your own!

Executed Projects (STATINS)

A third look: Digging in to the Phase 2b data presented at the AAC Conference for Merck's oral PCSK9 inhibitor, MK-0616, in patients with hypercholesterolemia
Ticker: MRK
Executed On: Mar 14, 2023 at 07:00 PM EDT
A second look: Digging in to the Phase 2b data presented at the AAC Conference for Merck's oral PCSK9 inhibitor, MK-0616, in patients with hypercholesterolemia
Ticker: MRK
Executed On: Mar 14, 2023 at 06:00 PM EDT
Digging in to the Phase 2b data presented at the AAC Conference for Merck's oral PCSK9 inhibitor, MK-0616, in patients with hypercholesterolemia
Ticker: MRK
Executed On: Mar 13, 2023 at 04:00 PM EDT
A Third View: Delving into the recent data from the ROSE2 clinical trial on obicetrapid by NewAmsterdam Pharma for the treatment of Heart Disease.
Ticker: NAMS
Executed On: Feb 27, 2023 at 11:00 AM EST
A Second View: Delving into the recent data from the ROSE2 clinical trial on obicetrapid by NewAmsterdam Pharma for the treatment of Heart Disease.
Ticker: NAMS
Executed On: Feb 09, 2023 at 03:00 PM EST
Delving into the recent data from the ROSE2 clinical trial on obicetrapid by NewAmsterdam Pharma for the treatment of Heart Disease.
Ticker: NAMS
Executed On: Feb 06, 2023 at 04:00 PM EST
A third look at how prescribing patterns will be affected for patients with high cholesterol after FDA clearance for 23andMe’s genetic reports to include predicted patient reaction to simvastatin based on SLCO1B1 genotype.
Ticker: ME
Executed On: Nov 18, 2022 at 03:00 PM EST
A second look at how prescribing patterns will be affected for patients with high cholesterol after FDA clearance for 23andMe’s genetic reports to include predicted patient reaction to simvastatin based on SLCO1B1 genotype.
Ticker: ME
Executed On: Nov 07, 2022 at 11:30 AM EST
A look at how prescribing patterns will be affected for patients with high cholesterol after FDA clearance for 23andMe’s genetic reports to include predicted patient reaction to simvastatin based on SLCO1B1 genotype.
Ticker: ME
Executed On: Nov 03, 2022 at 04:00 PM EDT

Upcoming & Overdue Catalysts (STATINS)

Don’t see a catalyst related to the keyword you care about? Create your own!

Strategic Initiatives (STATINS)

Don’t see a strategic initiative related to the keyword you care about? Create your own!